~~<i id='62082B73DC'><strike id='62082B73DC'><tt id='62082B73DC'><pre id='62082B73DC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：knowledge 2025-09-30 09:30:09 - browse：5974

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： AltruBio raises $225 million to develop ulcerative colitis drug

focus

hotspot

leisure time

AdobeWeneverwalkalone.Acrossthelandscapeofourbodies,trillionsofmicrobesaccompanyusonthejourneyoflife

WSS

EpiPen alternative approval delay highlights citizen petition issue

Deliver public health messages at the right time

Experts study whether long Covid risk adds up with each reinfection

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Chemotherapy before breast cancer surgery might fuel metastasis

Senators: Long

hotspot

Wikipedia

focus

Hepatitis C has a cure — but many Americans still lack access to it

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Moonlake's readout produced a cash windfall. Risks remain

FDA panel to weigh approval of NurOwn, controversial ALS drug

Affirmative action in medical school literally saved lives

Lasker Awards 2023: Winners in biomedical research

Peter Hotez and the public health issue of online harassment

Class action alleges UnitedHealth concealed DOJ probe

Heart attack and stroke risk calculators need revising

As billionaires fund anti

focus

How AI helped researchers track recovery from depression

Welsh Carson private equity firm escapes from FTC antitrust case

AltruBio raises $225 million to develop ulcerative colitis drug

It's been 20 years since Dolly the sheep. Where's my clone?

Why are Kaiser Permanente staff considering a strike?

Microbiome research is starting to find links to chronic diseases

hotspot

hotspot

hotspot

leisure time